These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33797059)

  • 1. Design and Analysis of a Biosimilar Bridging Study with a Prediction Interval-Based Consistency Test.
    Pan Z; Huang W; Pan J; Koch G
    Ther Innov Regul Sci; 2021 Jul; 55(4):765-772. PubMed ID: 33797059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References.
    Song F; Zheng X; Wang Y; Chow SC; Sun H
    AAPS J; 2021 Nov; 24(1):3. PubMed ID: 34850298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
    Tu CL; Wang YL; Hu TM; Hsu LF
    BioDrugs; 2019 Aug; 33(4):437-446. PubMed ID: 31111423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjustment for unbalanced sample size for analytical biosimilar equivalence assessment.
    Dong XC; Weng YT; Tsong Y
    J Biopharm Stat; 2017; 27(2):220-232. PubMed ID: 28060570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA's Approach to Regulating Biosimilars.
    Lemery SJ; Ricci MS; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2017 Apr; 23(8):1882-1885. PubMed ID: 28034906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample Size for Biosimilar Trials: In Defense of Synthesis.
    Clark T; Jo SJ; Phillips A
    Ther Innov Regul Sci; 2018 May; 52(3):300-305. PubMed ID: 29714537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
    Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
    BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From bioequivalence to biosimilars: How much do regulators dare?
    Weise M
    Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On Statistical Approaches for Demonstrating Analytical Similarity in the Presence of Correlation.
    Yang H; Novick S; Burdick RK
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):547-559. PubMed ID: 27325594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elastic meta-analytic-predictive prior for dynamically borrowing information from historical data with application to biosimilar clinical trials.
    Zhang W; Pan Z; Yuan Y
    Contemp Clin Trials; 2021 Nov; 110():106559. PubMed ID: 34506959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical Considerations on Clinical Efficacy Studies of Biosimilar for PMDA Submission.
    Asami Y; Pan J; Oh M; Sato A
    Ther Innov Regul Sci; 2020 Sep; 54(5):1134-1137. PubMed ID: 32128700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian adaptive design for biosimilar trials with time-to-event endpoint.
    Belay SY; Mu R; Xu J
    Pharm Stat; 2021 May; 20(3):597-609. PubMed ID: 33474838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity.
    Zeng D; Pan J; Hu K; Chi E; Lin DY
    J Biopharm Stat; 2018; 28(2):320-332. PubMed ID: 29173074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of tolerance intervals for assessing biosimilarity.
    Chen C; Hsiao CF
    Stat Med; 2020 Nov; 39(26):3806-3822. PubMed ID: 32754932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional consistency and sample size considerations in a multiregional equivalence trial.
    Wu SC; Xu JF; Zhang XJ; Li ZW; He J
    Pharm Stat; 2020 Nov; 19(6):897-908. PubMed ID: 32716135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parameters.
    Mielke J; Woehling H; Jones B
    Pharm Stat; 2018 May; 17(3):231-247. PubMed ID: 29424120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian methods for analysis of biosimilar phase III trials.
    Weiss RE; Xia X; Zhang N; Wang H; Chi E
    Stat Med; 2018 Sep; 37(20):2938-2953. PubMed ID: 29797335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinician's guide to biosimilars in oncology.
    Rugo HS; Linton KM; Cervi P; Rosenberg JA; Jacobs I
    Cancer Treat Rev; 2016 May; 46():73-9. PubMed ID: 27135548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.